Nothing Special   »   [go: up one dir, main page]

AU2003255355A1 - Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy - Google Patents

Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy

Info

Publication number
AU2003255355A1
AU2003255355A1 AU2003255355A AU2003255355A AU2003255355A1 AU 2003255355 A1 AU2003255355 A1 AU 2003255355A1 AU 2003255355 A AU2003255355 A AU 2003255355A AU 2003255355 A AU2003255355 A AU 2003255355A AU 2003255355 A1 AU2003255355 A1 AU 2003255355A1
Authority
AU
Australia
Prior art keywords
replacement therapy
increased
hormone replacement
receptor modulators
female fertility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003255355A
Inventor
Walter Elger
Alexander Hillisch
Gudrun Reddersen
Birgitt Schneider
Gerd Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10236405A external-priority patent/DE10236405A1/en
Application filed by Schering AG filed Critical Schering AG
Publication of AU2003255355A1 publication Critical patent/AU2003255355A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to novel compounds of general formula (I), to the production thereof and to pharmaceutical preparations containing these compounds. The inventive compounds are preferably used in female fertility testing and hormone replacement therapy.
AU2003255355A 2002-08-02 2003-08-01 Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy Abandoned AU2003255355A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40006502P 2002-08-02 2002-08-02
DE10236405.2 2002-08-02
DE10236405A DE10236405A1 (en) 2002-08-02 2002-08-02 New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders
US60/400,065 2002-08-02
PCT/EP2003/008572 WO2004014935A1 (en) 2002-08-02 2003-08-01 Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy

Publications (1)

Publication Number Publication Date
AU2003255355A1 true AU2003255355A1 (en) 2004-02-25

Family

ID=31716602

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003255355A Abandoned AU2003255355A1 (en) 2002-08-02 2003-08-01 Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy

Country Status (8)

Country Link
EP (1) EP1525215B1 (en)
JP (1) JP2005539016A (en)
AT (1) ATE338763T1 (en)
AU (1) AU2003255355A1 (en)
DE (1) DE50304970D1 (en)
DK (1) DK1525215T3 (en)
ES (1) ES2273061T3 (en)
WO (1) WO2004014935A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011762A1 (en) 2001-08-10 2003-02-10 Cosmo Spa 17ALPHA ESTERS, 21-DIHYDROXYPREGNENE, THEIR USE AS ANTI-ANDROGENETIC AGENTS AND PROCEDURES FOR THEIR PREPARATION
DE102006018869A1 (en) * 2006-04-13 2007-10-18 Bayer Schering Pharma Ag 17alpha-substituted 4- (3-oxoestra-4,9-diene-11beta-yl) -benzoic acid, its derivatives and processes for their preparation
KR20080031487A (en) * 2006-06-28 2008-04-08 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline forms of atorvastatin
JP5583976B2 (en) * 2007-03-07 2014-09-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Steroid derivatives as selective progesterone receptor modulators
ITMI20071616A1 (en) 2007-08-03 2009-02-04 Cosmo Spa ENZYMATIC PROCESS FOR THE OBTAINING OF 17-ALFA MONOESTERS OF CORTEXOLONE AND / OR ITS 9,11-DEIDRODERIVATI.
WO2010010201A1 (en) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Gene expression profile as a marker of endometrial receptivity
DE102009034367A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases
DE102009034368A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034366A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034526A1 (en) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases
EP2348318A1 (en) * 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
DE102010007719A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
PT3569697T (en) 2014-06-17 2022-05-02 Asherman Therapy S L Stem cell therapy in endometrial pathologies
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504421A1 (en) * 1985-02-07 1986-08-07 Schering AG, 1000 Berlin und 4709 Bergkamen 11 beta -Phenylgonanes, the preparation thereof and pharmaceutical products containing these
DE4332283A1 (en) * 1993-09-20 1995-04-13 Jenapharm Gmbh Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds
DE4332284C2 (en) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds
DE19745085A1 (en) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11β-Benzaldoxim-9alpha, 10alpha-epoxy-estr-4-ene derivatives, processes for their preparation and pharmaceutical preparations containing these compounds
DE19809845A1 (en) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds
PL198798B1 (en) * 1999-08-31 2008-07-31 Schering Ag Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
PE20010578A1 (en) * 1999-08-31 2001-06-04 Schering Ag MESOPROGESTINES (MODULAR PROGESTERONE RECEPTORS) FOR THE TREATMENT AND PREVENTION OF BENIGN HORMONE-DEPENDENT GYNECOLOGICAL DISORDERS
CA2383650A1 (en) * 1999-08-31 2001-04-19 Jenapharm Gmbh & Co. Kg Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
DE19961219A1 (en) * 1999-12-15 2001-07-19 Jenapharm Gmbh 11beta-phenyltratriene derivatives with fluoroalkyl groups in the aromatic side chain, their preparation and pharmaceutical compositions containing these compounds

Also Published As

Publication number Publication date
WO2004014935A1 (en) 2004-02-19
EP1525215B1 (en) 2006-09-06
ES2273061T3 (en) 2007-05-01
ATE338763T1 (en) 2006-09-15
DE50304970D1 (en) 2006-10-19
DK1525215T3 (en) 2007-01-15
JP2005539016A (en) 2005-12-22
EP1525215A1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
SE9904505D0 (en) Novel compounds
AU2003255355A1 (en) Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
AU6461600A (en) Substituted piperidine compounds useful as modulators of chemokine receptor activity
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
MY137535A (en) New pyrrolidinium derivatives
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
HK1048990A1 (en) Novel compounds.
MXPA02007942A (en) Pyrrolopyrimidinone derivatives, process of preparation and use.
AU2003228770A1 (en) Substituted pyrazolopyrimidines
IL164974A0 (en) Novel compounds and their use
HUP0102913A2 (en) Use of biogenic estrogen sulfamates for producing pharmaceutical compositions for hormone replacement therapy
TW261615B (en)
SE9902765D0 (en) Novel compounds
MY137144A (en) Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
AU2001232556A1 (en) Pyrimidine compounds and their use as modulators of chemokine receptor activity
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
IL157653A0 (en) Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
DE60221537D1 (en) PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOCIN RECEPTOR ACTIVITY
HRP20010969B1 (en) Novel piperazinylalkylthiopyrimidine derivatives,
AU5692500A (en) Piperazine derivatives as modulators of chemokine receptor activity
AU7525398A (en) Inhibitors for urokinase receptor
AU2002248531A1 (en) Pyrazolopyriadine derivatives
MXPA02002007A (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase